Routine FDA Surveillance Inspections Prioritized Based on Site Compliance History

The FDA has updated how the Office of Pharmaceutical Quality (OPQ) will select manufacturing sites for routine surveillance inspection, using information about the compliance history of sites “to promote parity in inspectional coverage and the effective and efficient use of FDA resources to address the most significant public health risks.”
Source: Drug Industry Daily